Literature DB >> 11580309

Comparative efficacy and tolerability of drug treatments for bipolar disorder.

S M Strakowski1, M P DelBello, C M Adler.   

Abstract

Lithium has been the backbone of treatment for bipolar disorder for several decades, although recent advances have identified a number of other medications that have efficacy in treating various phases of the illness. These include the antiepileptic drugs valproate semisodium (divalproex sodium) and carbamazepine and some new antiepileptic drugs (e.g. lamotrigine and topiramate), and the atypical antipsychotics (e.g. olanzapine, clozapine and risperidone). Conventional antipsychotics continue to be used frequently in bipolar disorder, although they may be somewhat less effective than other treatments. Otherwise, to date, none of these treatments have been shown to be consistently more effective than any other, so that drug adverse effects and tolerability often dictate which agents are used in an individual patient. Drugs commonly used for the treatment of bipolar disorder are generally tolerated by most patients in large samples. However, the unique adverse effect signature of a drug will often suggest that it will be less tolerable in some patients than in others. Identifying a specific treatment for a specific patient requires a careful individualised assessment of the risk of adverse effects for that patient's unique circumstances.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11580309     DOI: 10.2165/00023210-200115090-00004

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  108 in total

1.  Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.

Authors:  G E Solomon
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

2.  Zonisamide-induced mania.

Authors:  C L Charles; L Stoesz; G Tollefson
Journal:  Psychosomatics       Date:  1990       Impact factor: 2.386

3.  Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.

Authors:  H M Hamer; S Knake; U Schomburg; F Rosenow
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

4.  Lamotrigine treatment of rapid cycling bipolar disorder.

Authors:  V Kusumakar; L N Yatham
Journal:  Am J Psychiatry       Date:  1997-08       Impact factor: 18.112

5.  Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.

Authors:  C M Beasley; M A Dellva; R N Tamura; H Morgenstern; W M Glazer; K Ferguson; G D Tollefson
Journal:  Br J Psychiatry       Date:  1999-01       Impact factor: 9.319

6.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Authors:  M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-09

7.  Safety of topiramate: adverse events and relationships to dosing.

Authors:  S D Shorvon
Journal:  Epilepsia       Date:  1996       Impact factor: 5.864

8.  An audit of topiramate use in a general neurology clinic.

Authors:  P Crawford
Journal:  Seizure       Date:  1998-06       Impact factor: 3.184

Review 9.  Clinical studies on the use of lamotrigine in bipolar disorder.

Authors:  J R Calabrese; D J Rapport; M D Shelton; M Kujawa; S E Kimmel
Journal:  Neuropsychobiology       Date:  1998-10       Impact factor: 2.328

10.  Clozapine for treatment-refractory mania.

Authors:  J R Calabrese; S E Kimmel; M J Woyshville; D J Rapport; C J Faust; P A Thompson; H Y Meltzer
Journal:  Am J Psychiatry       Date:  1996-06       Impact factor: 18.112

View more
  11 in total

Review 1.  Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions.

Authors:  Trino Baptista; N M K Ng Ying Kin; Serge Beaulieu
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

2.  Pharmacoeconomic analyses using discrete event simulation.

Authors:  J Jaime Caro
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

3.  The importance of drug adverse effects compared with seizure control for people with epilepsy: a discrete choice experiment.

Authors:  Andrew Lloyd; Emma McIntosh; Martin Price
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 4.  Treatment research in bipolar disorder: issues and recommendations.

Authors:  Ross J Baldessarini
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 5.  Olanzapine: a review of its use in the management of bipolar I disorder.

Authors:  Paul L McCormack; Lynda R Wiseman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

6.  Broadening the diagnosis of bipolar disorder: benefits vs. risks.

Authors:  Stephen M Strakowski; David E Fleck; Mario Maj
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

Review 7.  Lamotrigine: a review of its use in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Comparative peptidomics analysis of neural adaptations in rats repeatedly exposed to amphetamine.

Authors:  Elena V Romanova; Ji Eun Lee; Neil L Kelleher; Jonathan V Sweedler; Joshua M Gulley
Journal:  J Neurochem       Date:  2012-09-03       Impact factor: 5.372

9.  Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials.

Authors:  Richard H Weisler; Robert Hirschfeld; Andrew J Cutler; Thomas Gazda; Terence A Ketter; Paul E Keck; Alan Swann; Amir Kalali
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

10.  Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder.

Authors:  Richard H Weisler; Amir H Kalali; Andrew J Cutler; Thomas D Gazda; Lawrence Ginsberg
Journal:  Psychiatry (Edgmont)       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.